Key facts
- Faeth’s last known valuation is $200.0M (Feb 2026).
- It has raised $92.0M; the latest was Merger/Acquisition ($200.0M) in Feb 2026.
- Notable investors include Khosla Ventures, B Capital Group, S2G Investments, AgFunder, Digitalis Ventures — 14 tracked in total.
- Status: Acquired/Merged.
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Faeth
- ·The full record, as it builds
Funding rounds
No funding rounds for Faeth are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Faeth
Operator of a data-driven, evidence-based healthcare company intended to use a deep mechanistic understanding of cancer metabolism to help in the treatment of cancer. The company is focused on matching specific diets with tumor genotypes and treatment regimens that would limit the supply of energy and building blocks that tumors require to grow, helping patients in their cancer treatments.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2019
- Employees
- 28
- Website
- faeththerapeutics.com/
- Ownership
- Acquired/Merged
Faeth doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Faeth shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Faeth in its N-PORT filings yet. We sweep new filings monthly.